Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

papillary renal cell carcinoma (HPRCC) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

papillary renal cell carcinoma

MONDO:0017884

Also known as:HPRCCchromophil carcinoma of kidneychromophil carcinoma of the kidney

Find Clinical TrialsTrials

Overview

A rare subtype of renal cell carcinoma, arising from the renal tubular epithelium and showing a papillary growth pattern, which typically manifests with hematuria, flank pain, palpable abdominal mass or nonspecific symptoms, such as fatigue, weight loss or fever. Symptoms related to metastatic spread, such as bone pain or persistent cough, are frequently associated since early diagnosis is not common. It is typically multifocal, bilateral, and in most cases sporadic, although different hereditary syndromes, such as Hereditary leiomyoma renal cell carcinoma, Birt-Hogg-DubC) syndrome and Tuberous sclerosis, may predispose to the development of papillary renal cell carcinoma.

Clinical Trials19 registered · 5 recruiting

Diagnosis

Biomarker and diagnostic research for papillary renal cell carcinoma has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

19 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE3, 8 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05665361](https://clinicaltrials.gov/study/NCT05665361)

Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 4:27 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:319298

GARD

Genetic and Rare Diseases Info Center

GARD:9572

Questions for Your Care Team

→Are any of the 19 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	48	29%
Testing and diagnosis research	31	19%
Research summaries	28	17%
Laboratory research	25	15%
Disease patterns and progression	16	10%
Clinical study results	7	4%
New treatment approaches	6	4%
Other research	4	2%

papillary renal cell carcinoma

Overview

Diagnosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications